Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ARVN
ARVN logo

ARVN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Arvinas Inc (ARVN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
7.760
1 Day change
0.78%
52 Week Range
14.510
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ARVN is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has some positive fundamental catalysts from recent FDA approval and a commercial partnership, but the current technical trend is still weak, insider selling is heavy, and there is no Intellectia proprietary buy signal. For an impatient investor who does not want to wait for a better entry, this is still not an attractive immediate buy.

Technical Analysis

The chart setup is bearish to neutral. MACD histogram is negative and still below zero, showing weak momentum. RSI_6 at 32.35 is near oversold but not yet a clear reversal signal. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which confirms the longer-term trend is still under pressure. Price at 8.98 is just above support at 8.497 and below pivot resistance at 9.081, so the stock is trading near support but has not confirmed a breakout. The pattern-based outlook also shows weak near-term performance, with a 60% chance of a -3.5% move next day and slightly negative next-week expectations.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Options sentiment is mixed. The low open interest put-call ratio of 0.21 suggests more calls than puts outstanding, which leans bullish. However, the option volume put-call ratio of 1.88 shows more put trading activity today, signaling hedging or near-term bearish sentiment. Implied volatility at 67.78 is elevated versus historical volatility of 41.55, so the market is pricing in meaningful movement. Overall, options sentiment is not strongly bullish despite the low OI put-call ratio.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
10
Buy
6

Positive Catalysts

  • ["Recent FDA approval of Veppanu for ESR1m ER+ HER2- breast cancer patients is a meaningful de-risking event.", "Arvinas and Pfizer entered a license agreement with Rigel Pharmaceuticals for Veppanu rights, and the deal includes $85M upfront plus up to $320M in milestones.", "BTIG, Barclays, Citi, and BofA all raised price targets in recent updates, showing improving analyst expectations.", "The commercial partnership removes a key overhang and provides cash to reinvest into the pipeline."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh catalyst driving the stock now.", "Insiders are selling, and selling increased 504.89% over the last month, which is a negative signal.", "Hedge funds are neutral with no strong accumulation trend.", "Technical trend remains bearish, with MACD below zero and moving averages stacked bearishly.", "There is no AI Stock Pick signal and no recent SwingMax signal.", "No recent congress trading data was available."]

Financial Performance

No usable financial snapshot was provided because of a data error, so the latest quarter season cannot be assessed from the supplied numbers. The only financial-related event available is the commercial partnership announced alongside Q1 results, which brought in $85M upfront and future milestone potential. That improves liquidity and supports pipeline investment, but I cannot verify revenue, earnings, or growth metrics from the provided financial data.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment has improved over the last several updates. BofA raised its target to $16 and stayed Neutral, citing the need for more clinical de-risking. BTIG lifted its target to $18 and kept Buy, Barclays raised its target to $20 and kept Overweight, and Citi raised its target to $24 and kept Buy after FDA approval. The Wall Street pros are generally constructive on the company’s de-risking progress and pipeline, but BofA’s Neutral view highlights the main con: the early-stage pipeline still needs more clinical proof. Overall, analysts are becoming more bullish, but the consensus is not yet a strong unanimous buy.

Wall Street analysts forecast ARVN stock price to rise
4 Analyst Rating
Wall Street analysts forecast ARVN stock price to rise
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.740
sliders
Low
15
Averages
16
High
18
Current: 7.740
sliders
Low
15
Averages
16
High
18
BofA
Tazeen Ahmad
Neutral
maintain
$14 -> $16
AI Analysis
2026-05-13
Reason
BofA
Tazeen Ahmad
Price Target
$14 -> $16
AI Analysis
2026-05-13
maintain
Neutral
Reason
BofA analyst Tazeen Ahmad raised the firm's price target on Arvinas (ARVN) to $16 from $14 and keeps a Neutral rating on the shares. Arvinas and Pfizer (PFE) entered into a license agreement with Rigel Pharmaceuticals (RIGL) for the rights for Veppanu. The firm believes Rigel makes sense as a commercial partner given the company already has an established U.S. commercial presence in oncology. BofA told investors that it still thinks Arvinas' early-stage pipeline needs clinical de-risking.
BTIG
Buy
upgrade
$16 -> $18
2026-05-13
Reason
BTIG
Price Target
$16 -> $18
2026-05-13
upgrade
Buy
Reason
BTIG raised the firm's price target on Arvinas (ARVN) to $18 from $16 and keeps a Buy rating on the shares. Along with its Q1 results, the company announced it was selected by Rigel Pharmaceuticals (RIGL) as the third-party commercial partner for VEPPANU, receiving $85M upfront and up to $320M in future milestones, which removes the key commercial overhang, gets VEPPANU to patients, and provides Arvinas proceeds to reinvest into its wholly owned pipeline, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ARVN
Unlock Now

People Also Watch